Friday 6 November 2026
Export INSP’s income statement to Excel — free account
Inspire Medical Systems, Inc.
INSP Healthcare Medical Devices
Inspire Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $912.0 million, up 13.6% from fiscal 2024.
- Revenue
- −7.93%
- EPS
- −348.0%
- Free cash flow
- −33.1%
Quarter to September 2026, against a year earlier
64.22
2.31
−3.47%
Follow INSP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
18.37 | 11.39 | 9.57 | 19.95 |
P/S ratio |
2.97 | 1.62 | 1.43 | 2.28 | |
P/FCF ratio |
34.52 | 15.31 | 10.99 | 20.50 | |
P/Operating CF |
51.62 | 115.21 | 55.38 | 43.22 | |
P/B ratio |
3.47 | 1.87 | 1.56 | 2.43 | |
Price to Tangible BV |
3.47 | 1.87 | 1.56 | 2.43 | |
EV/Sales |
2.64 | 1.32 | 1.09 | 1.92 | |
EV/EBITDA |
38.86 | 18.45 | 13.93 | 50.93 | |
EV/Operating CF |
20.60 | 8.84 | 6.21 | 12.51 | |
EV/FCF |
30.71 | 12.47 | 8.33 | 17.25 | |
Quick Ratio |
4.46 | 4.35 | 5.96 | 4.45 | |
Current Ratio |
6.08 | 6.34 | 8.55 | 6.45 | |
Net Debt/EBITDA |
(6.22) | (76.67) | (83.38) | 13.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.06 | 1.11 | 1.04 | 1.00 | |
Operating CF/Net income |
0.39 | (1.14) | 73.97 | (1.90) | |
Capex/Depreciation |
(3.09) | (2.02) | (2.10) | (1.58) | |
Interest Coverage |
365.96 | — | — | — | |
Research and Development Expense of Revenue |
9.27% | 12.62% | 12.31% | 10.73% | |
Selling, General and Administrative Expense of Revenue |
60.19% | 74.40% | 73.42% | 89.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.41% | 15.00% | 15.57% | 13.02% | |
Graham Net Nets |
0.17 | 0.30 | 0.40 | 0.25 | |
Graham Number |
54.81 | 53.05 | 54.79 | 47.29 | |
Earnings Yield |
5.44% | 8.78% | 10.45% | 5.01% | |
Free Cash Flow Yield |
2.90% | 6.53% | 9.10% | 4.88% | |
Revenue per Share |
9.16 | 7.13 | 6.96 | 7.14 | |
Operating CF per Share |
1.79 | 0.45 | 0.81 | 1.60 | |
Capex per Share |
(0.36) | (0.34) | (0.32) | (0.26) | |
Free Cash Flow per Share |
1.42 | 0.11 | 0.49 | 1.34 | |
Cash per Share |
10.50 | 9.89 | 11.12 | 11.34 | |
Shareholders Equity per Share |
26.60 | 27.61 | 28.63 | 28.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.60 | 27.61 | 28.63 | 28.59 | |
Free Cash Flow |
41.81 | 3.12 | 14.07 | 38.88 | |
Working Capital |
487.60 | 477.40 | 537.49 | 530.29 | |
Capital Expenditures |
(10.66) | (9.73) | (9.16) | (7.54) | |
Net Current Asset Value |
457.50 | 447.78 | 508.26 | 501.54 | |
EV/EBIT |
47.30 | 23.51 | 18.02 | 107.11 | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.04 | |
Price to Operating Income |
53.16 | 28.85 | 23.77 | 127.29 | |
| Other line items | |||||
Average Receivables |
106.38 | 98.86 | 120.51 | 106.35 | |
Average Payables |
37.63 | 35.49 | 40.13 | 48.66 | |
Average Inventory |
112.71 | 132.98 | 146.04 | 160.37 | |
Average Assets |
857.85 | 821.09 | 864.09 | 880.37 | |
Average Common Equity |
735.43 | 714.04 | 751.70 | 746.70 |
Columns are period end dates · fundamentals updated 5 Nov 2026